PDS Biotechnology (NASDAQ:PDSB – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.03), FiscalAI reports.
PDS Biotechnology Stock Up 0.8%
Shares of PDSB stock traded up $0.00 on Friday, hitting $0.23. 662,674 shares of the stock were exchanged, compared to its average volume of 956,903. The company has a current ratio of 2.26, a quick ratio of 2.26 and a debt-to-equity ratio of 2.73. The firm has a market capitalization of $13.14 million, a P/E ratio of -0.35 and a beta of 1.62. PDS Biotechnology has a fifty-two week low of $0.22 and a fifty-two week high of $1.55. The business has a 50-day moving average of $0.80 and a 200 day moving average of $0.86.
Hedge Funds Weigh In On PDS Biotechnology
Large investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in shares of PDS Biotechnology during the 4th quarter worth about $25,000. Marshall Wace LLP bought a new position in PDS Biotechnology in the second quarter valued at approximately $91,000. Jane Street Group LLC acquired a new position in shares of PDS Biotechnology during the 2nd quarter worth approximately $92,000. Susquehanna International Group LLP increased its position in shares of PDS Biotechnology by 603.7% during the 3rd quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock worth $95,000 after purchasing an additional 80,937 shares during the last quarter. Finally, Commonwealth Equity Services LLC raised its stake in shares of PDS Biotechnology by 117.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock worth $151,000 after purchasing an additional 106,300 shares in the last quarter. Institutional investors and hedge funds own 26.84% of the company’s stock.
Analyst Ratings Changes
PDS Biotechnology Company Profile
PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.
Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.
Featured Stories
- Five stocks we like better than PDS Biotechnology
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
- CAVA Earnings: The Easiest Comp of the Year Meets a Tough Valuation
- Joint Operations: Curaleaf Makes a Play for Aurora Cannabis
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
